Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Tax Provisions (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Tax Provisions for 16 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 143.3% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $672000.0, a 88.92% decrease, with the full-year FY2025 number at $672000.0, down 88.92% from a year prior.
  • Tax Provisions was -$1.1 million for Q4 2025 at Anika Therapeutics, down from $939000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $9.1 million in Q4 2023 to a low of -$3.4 million in Q4 2021.
  • A 5-year average of $793600.0 and a median of $71500.0 in 2024 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: crashed 269.57% in 2022, then skyrocketed 552.33% in 2024.
  • Anika Therapeutics' Tax Provisions stood at -$3.4 million in 2021, then skyrocketed by 295.71% to $6.6 million in 2022, then soared by 37.62% to $9.1 million in 2023, then plummeted by 72.91% to $2.5 million in 2024, then tumbled by 143.3% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Tax Provisions are -$1.1 million (Q4 2025), $939000.0 (Q3 2025), and $700000.0 (Q2 2025).